Spin-Off

Freshly independent, MiniMed reports record sales and a robust product pipeline, signaling a focused strategy to dominate the competitive diabetes tech market.

The retirement of 25-year veteran Tracy Skeans prompts Yum! Brands to split its COO role, creating a Chief Scale Officer to drive tech and global growth.

Aethlon Medical's upcoming financial report is more than a balance sheet; it's a test of viability for its revolutionary Hemopurifier blood filter.

Alarum Technologies will report Q1 results on May 28. Investors are watching to see if massive AI investments are fueling sustainable growth or just costs.

A new six-month semaglutide implant is entering clinical trials, aiming to solve the adherence crisis plaguing GLP-1 drugs like Ozempic and Wegovy.

With a 2027 deadline looming and prices soaring, a junior miner's Nevada project could become vital for America's defense supply chain.

Resideo posted strong Q1 results with an 8% revenue jump to $1.91B, setting a positive stage for the planned separation of its ADI distribution arm.

Linea's ZK rollup stack is now Lineth, a new Linux Foundation project. The move signals a major shift towards vendor-neutral governance for Ethereum scaling.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

Meren Energy's upcoming Q1 2026 results will be scrutinized for its performance in Africa's deepwater projects amidst soaring oil prices and strategic shifts.

Boston-based Metalenz unveils Polar ID, a secure, invisible face unlock system that promises a true all-screen future for Android smartphones.

Corteva's seed business will become Vylor, a new powerhouse poised to revolutionize farming with hybrid wheat, gene editing, and a century-long legacy.

After a record 2025 but a mixed Q4, the aerospace supplier's upcoming earnings will reveal its resilience against renewed supply chain disruptions.

With new federal and distribution partners, Cornelis aims to break vendor lock-in in high-performance computing with its CN5000 networking solutions.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

Amidst industry consolidation, XanEdu spins off to refocus on affordable, custom curriculum, signaling a strategic shift toward specialization in education.

Pictet Asset Management launches two active ETFs for U.S. investors, offering a unique emerging markets strategy that sidesteps China and tech concentration.

With its fiscal 2026 results imminent, STERIS faces high expectations amid market pressures, offering a key indicator for the global healthcare sector.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

The fintech firm spins out from its parent, lowering credit score requirements and promising zero-day closings in a bold move to unlock home equity.